Source link : https://www.newshealth.biz/health-news/enhertu-gets-tumor-agnostic-fda-approval-for-her2-positive-cancers/
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers. The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According to an FDA statement, the approval had support from three clinical trials of patients with previously treated unresectable/metastatic […]
Author : News Health
Publish date : 2024-04-05 21:08:40
Copyright for syndicated content belongs to the linked Source.
Categories